ACRS Company Profile and Key Details

Q: Who are the executives of ACRS?

Mr. Matthew Rothman J.D.Gen. Counsel & Corporation Sec.Dr. Gail Cawkwell M.D., Ph.D.Chief Medical OfficerMr. Frank RuffoCo-Founder, Chief Financial Officer , Sec. & TreasurerMr. Robert A. Doody Jr.Vice President of Investor RelationsDr. Paul S. Changelian Ph.D.Senior Vice President of BiologyDr. Neal S. Walker D.O.Co-Founder & ChairmanDr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryDr. Douglas J. Manion Frcp(C), M.D.Chief Executive Officer, Pres & DirectorDr. Joseph MonahanChief Scientific OfficerMr. James LoeropChief Bus. OfficerDr. Ian Anderson Ph.D.Executive Vice President of Translational R&DMr. Gary A. DeCrescenzoSenior Vice President of Pharmaceutical R&DMr. Kevin BalthaserChief Financial OfficerDr. Joseph Monahan Ph.D.Chief Scientific Officer

NASDAQ : ACRS

Aclaris Therapeutics

$3.05

0.18+6.27%

At Close 4:00 PM

72.81

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aclaris Therapeutics, Inc. (ACRS) stock surged +6.27%, trading at $3.05 on NASDAQ, up from the previous close of $2.87. The stock opened at $2.80, fluctuating between $2.75 and $3.12 in the recent session.

Stock Snapshot

2.87

Prev. Close

330.45M

Market Cap

2.75

Day Low

-1.93

P/E Ratio

-1.58

EPS (TTM)

-1.12

Cash Flow per Share

2.8

Open

108.35M

Number of Shares

3.115

Day High

85.19%

Free Float in %

2.22

Book Value

4.85M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 02, 2026	2.83	3.11	2.75	3.05	4.87M
Feb 27, 2026	3.08	3.14	2.85	2.87	1.57M
Feb 26, 2026	3.17	3.17	2.80	3.13	1.5M
Feb 25, 2026	3.38	3.42	3.24	3.31	1.04M
Feb 24, 2026	3.27	3.44	3.25	3.36	1.56M
Feb 23, 2026	3.24	3.31	3.15	3.25	1.81M
Feb 20, 2026	3.20	3.33	3.13	3.24	1.38M
Feb 19, 2026	3.15	3.29	3.12	3.23	1.28M
Feb 18, 2026	3.28	3.28	3.11	3.17	980.68K
Feb 17, 2026	3.19	3.38	3.12	3.26	1.15M
Feb 13, 2026	3.36	3.40	3.17	3.19	766.16K
Feb 12, 2026	3.42	3.43	3.25	3.36	701.88K
Feb 11, 2026	3.65	3.68	3.35	3.39	821.52K
Feb 10, 2026	3.72	3.78	3.60	3.65	701.77K
Feb 09, 2026	3.56	3.75	3.42	3.69	620.06K
Feb 06, 2026	3.36	3.65	3.30	3.57	1.57M
Feb 05, 2026	3.54	3.65	3.37	3.39	718.68K
Feb 04, 2026	3.50	3.60	3.42	3.54	886.92K
Feb 03, 2026	3.55	3.59	3.42	3.47	980.95K
Feb 02, 2026	3.46	3.73	3.38	3.61	1.76M

Contact Details

Wayne, PA 19087

United States

https://www.aclaristx.com 484 324 7933

About Company

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Stock Peers

IDXX

-20.03-3.05%

IDEXX Laboratories, Inc.$636.70 MEDP

5.71+1.26%

Medpace Holdings, Inc.$457.47 NTRA

-7.87-3.78%

Natera, Inc.$200.17 ILMN

-1.57-1.17%

Illumina, Inc.$132.89 ICLR

0.13+0.12%

ICON Public Limited Company$108.27 EXAS

-0.03-0.03%

Exact Sciences Corporation$103.35 GH

-1.67-1.78%

Guardant Health, Inc.$92.23 BLLN

2.32+3.04%

BillionToOne, Inc.$78.65 RDNT

5.41+7.75%

RadNet, Inc.$75.22 GRAL

-0.6-1.13%

GRAIL, Inc.$52.63

Company Overview

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) closed at $3.05 USD, gaining $0.18 (6.27%) from the previous close of $2.87. The stock is currently mid-range between its 52-week high and low $1.05 and $4.89. With a market capitalization of about $330.45 million, Aclaris Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.86). Key stats such as the average daily volume over the past year has been around 1.86 million shares, trading with heavier-than-usual volume. Headquartered in Wayne, PA, Aclaris Therapeutics, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Neal S. Walker, the company employs approximately 61 people and listed since October 06, 2015. Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States.

Technical Performance

ACRS has shown sold momentum, gaining 66.54% over the past week and 133.16% over the past quarter, though year-to-date performance is up 47.18%. Short-term trend indicators are bearishly aligned (SMA20 -7.6%, SMA50 -3.99%, SMA200 39.79%). The stock’s 14-day RSI is 43.46 (neutral), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -35.99% below its high and over 198.1% above its low. Average 10-day trading volume of 1.96 million shares is in line with the 3-month average of 1.86 million, indicating normal recent market interest.

Valuation Metrics

Aclaris Therapeutics, Inc. trades at a P/E ratio of -5.81, slightly below the S&P 500 average, with a price-to-sales ratio of 42.57 and a price-to-book ratio of 3.66 trading at moderately above to book value. The P/FCF stands at -7.07, also above market averages.

Dividend & Fair Value

Aclaris Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.01. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Aclaris Therapeutics, Inc. generated EPS of -$1.38 over the past year. Five-year average earnings growth is 15.24%. Wall Street analysts project EPS growth of 27.1% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.14. Next year's EPS is expected at $18.80. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $6.00. The high target offers 424.59% upside. The low target suggests 96.72% downside. The mean target is $14.17. This offers 364.59% upside. Aclaris Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -14.87%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -21.05% in August 07, 2024.

Shareholding & Insider Activity

Aclaris Therapeutics, Inc. has 108.35 million shares outstanding. The public float is 91.28 million shares, elevated short interest at 5.36% of float. This equals 4.88 million shares. The short ratio is 1.74 days. Institutional investors hold 82.54% of the float. Insiders own 2.71%. Leonard Braden Michael holds 14.25 million shares, Walker Neal has 1.27 million shares and Flynn James E has 964.10 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Aclaris Therapeutics generated $31.25M in revenue, or $0.45 per share. Gross margin was 42.14%, operating margin -311.55%, and net profit margin -283.15%. Returns are negative, with ROA at -44.82% and ROE at -56.29%.
On valuation metrics, Aclaris Therapeutics trades at a P/E of -5.81, P/S of 42.57 and P/B of 3.66. The current ratio is 5.28 and quick ratio is 5.28. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2037.28 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of -12.80.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Aclaris Therapeutics posted revenue of $31.25M, down slightly from $29.75M in the prior quarter. Gross profit was $13.17M (margin 42.14%). Operating income was - $97.36M (margin -311.6%). Net income was- $88.48M (EPS - $1.27).
The company ended the quarter with $119.11M in cash and short-term investments, a total debt of $426.00K, and net debt of - $39.45M. Total assets were $197.41M, with equity of $157.18M. Financials further reflected weakness, with operating cash flow of - $78.33M, free cash flow of - $79.63M, and capital expenditures of - $1.31M.

Price Forecast & Outlook

Our AI price prediction model suggests that Aclaris Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.33%, with price expected at $3.04 by March 13, 2026, within a range of $2.43 to $3.70 3-Month Outlook: Projected rise of 75.74%, reaching $5.36 by May 28, 2026, with a range of $5.03 to $5.73. 1-Year Outlook: Projected gain of 526.56%, with price at $19.11 by February 26, 2027, within a range of $9.28 to $28.78.

Key Takeaways

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) shares are up 47.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Aclaris Therapeutics, Inc. trading at a premium to the broader market with a P/E of -5.81. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $28.41, suggesting 831.48% upside. Our AI forecast model points to short-term weakness (-0.33% over two weeks), a medium-term rise (75.74% over three months), and a longer-term gain (526.56% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Aclaris Therapeutics, Inc. (ACRS) stock price?

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) stock price is $3.05 in the last trading session. During the trading session, ACRS stock reached the peak price of $3.12 while $2.75 was the lowest point it dropped to. The percentage change in ACRS stock occurred in the recent session was 6.27% while the dollar amount for the price change in ACRS stock was $0.18.

ACRS's industry and sector of operation?

The NASDAQ listed ACRS is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Aclaris Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ACRS?

Mr. Matthew Rothman J.D.
Gen. Counsel & Corporation Sec.
Dr. Gail Cawkwell M.D., Ph.D.
Chief Medical Officer
Mr. Frank Ruffo
Co-Founder, Chief Financial Officer , Sec. & Treasurer
Mr. Robert A. Doody Jr.
Vice President of Investor Relations
Dr. Paul S. Changelian Ph.D.
Senior Vice President of Biology
Dr. Neal S. Walker D.O.
Co-Founder & Chairman
Dr. Jon Jacobsen Ph.D.
Senior Vice President of Chemistry
Dr. Douglas J. Manion Frcp(C), M.D.
Chief Executive Officer, Pres & Director
Dr. Joseph Monahan
Chief Scientific Officer
Mr. James Loerop
Chief Bus. Officer
Dr. Ian Anderson Ph.D.
Executive Vice President of Translational R&D
Mr. Gary A. DeCrescenzo
Senior Vice President of Pharmaceutical R&D
Mr. Kevin Balthaser
Chief Financial Officer
Dr. Joseph Monahan Ph.D.
Chief Scientific Officer

How ACRS did perform over past 52-week?

ACRS's closing price is 190.48% higher than its 52-week low of $1.05 where as its distance from 52-week high of $4.89 is -37.63%.

How many employees does ACRS have?

Number of ACRS employees currently stands at 61.

Link for ACRS official website?

Official Website of ACRS is: https://www.aclaristx.com

How do I contact ACRS?

ACRS could be contacted at phone 484 324 7933 and can also be accessed through its website. ACRS operates from 640 Lee Road, Wayne, PA 19087, United States.

How many shares of ACRS are traded daily?

ACRS stock volume for the day was 4.85M shares. The average number of ACRS shares traded daily for last 3 months was 1.86M.

What is the market cap of ACRS currently?

The market value of ACRS currently stands at $330.45M with its latest stock price at $3.05 and 108.35M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	61
Beta	0.86
Sales or Revenue	$31.25M
5Y Sales Change%	0.46%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

ACRS Company Profile and Key Details

Aclaris Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Company Overview

Price Forecast & Outlook

Key Takeaways